Tom Bumol

Tom Bumol has extensive experience in the biotechnology and immunology sectors, currently serving as a member of the Board of Directors for Tentarix Biotherapeutics, Spine BioPharma, and Omeros Corporation, along with a position on the Scientific Advisory Board for CytoReason, Neurocrine Biosciences, and ProFound Therapeutics. Prior to their current roles, Tom Bumol held significant leadership positions, including Executive Vice President at the Allen Institute for Immunology until August 2022, and Senior Vice President of Biotechnology and Immunology Research at Eli Lilly until December 2017, where a 25-year tenure included various roles in Lilly Research Laboratories. Tom Bumol began their career as a postdoctoral associate at Scripps Research after earning a B.S. in Microbiology from the University of Michigan and a Ph.D. in Microbiology/Immunology from the University of Minnesota.